. Here, the mechanisms underlying PP1 inhibition and the kinase/PP1 cross-talk mediated by CPI-17 and its related proteins, PHI, KEPI, and GBPI, are discussed.The reciprocal activities of protein kinases and phosphatases determine protein phosphorylation levels in cells. PP1 2 dephosphorylates phospho-Ser/Thr residues of proteins to regulate multiple signaling pathways at various cellular loci (1-3). Cellular PP1 is associated with PP1 regulatory proteins/subunits at their PP1-binding site, known as the RVXF motif. The binding of PP1 regulatory proteins thus confers substrate specificity and localization on cellular PP1. Nearly 100 polypeptides have been identified as PP1 regulatory proteins, and these account for the wide spectrum of PP1 function (1-3). In addition, eukaryotic cells express several PP1 inhibitor proteins that play important roles in regulating cellular PP1. The first generation of PP1 inhibitor proteins involves inhibitor-1, inhibitor-2, DARPP32, and NIPP-1, which potently inhibit the free catalytic subunit of PP1, but these inhibitor proteins were much less potent toward purified PP1 holoenzymes, MLCP and glycogen-bound PP1. Therefore, cellular PP1 holoenzymes were thought to undergo subunit dissociation prior to the inhibition of PP1 by the inhibitor proteins (1, 2). However, the number of PP1 holoenzymes that do undergo subunit dissociation in cells remains unclear.MLCP is a trimeric PP1 holoenzyme, consisting of a PP1∂ isoform and a regulatory complex of MYPT1 (aka MBS, M110) and a 21-kDa accessory subunit, and vital to control cellular phosphorylation in response to various signals (4). MYPT1 and PP1 bind through the MYPT1 KVKF segment, as well as its eight-repeat ankyrin motif at the N-terminal domain (5). Binding of the N-terminal 300-residue domain of MYPT1 is sufficient to allosterically regulate PP1 activity. The MYPT1 C-terminal domain directly binds to substrates, including myosin and ezrin/radixin/moesin (4). MLCP activity is reversibly regulated in response to various signals. For example, in smooth muscle, activation of the G-protein-coupled receptor inhibits MLCP, resulting in increased Ca 2ϩ sensitivity of myosin phosphorylation and contraction, whereas cyclic nucleotide signals can activate MLCP to induce smooth muscle relaxation (6). MLCP inhibition occurs upon MYPT1 phosphorylation at Thr 696 and Thr 853 (4). On the other hand, protein kinase G can activateMLCP(7).TheseregulatorysignalsareMYPT1isoform-dependent (8), suggesting an important role for MYPT1 in MLCP regulation. In addition, we identified the MLCP inhibitor protein, named CPI-17, which transduces G-protein signals into MLCP inhibition (9, 10). Based on sequence similarity, three CPI-17 homologs in the human genome, PHI, KEPI, and GBPI, were characterized as PP1 inhibitors (11-13). Each CPI-17 family member carries a PHIN domain, in which the sequences are Ͼ41% identical to CPI-17 (Fig. 1A). Indeed, all CPI-17 family members potently inhibit MLCP activity, which suggests new avenues for PP1 holoenzyme inhibition. ...